# Intranasal Insulin and Its Effect on Postprandial Metabolism in Comparison to Subcutaneous Insulin

> **NCT00850161** · PHASE2 · WITHDRAWN · sponsor: **CPEX Pharmaceuticals Inc.**

## Conditions studied

- Type 1 Diabetes Mellitus

## Interventions

- **DRUG:** aspart
- **DRUG:** Nasulin™

## Key facts

- **NCT ID:** NCT00850161
- **Lead sponsor:** CPEX Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2009-07
- **Primary completion:** 2009-08
- **Final completion:** 2010-09
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Business purposes.
- **Last updated:** 2016-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00850161

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00850161, "Intranasal Insulin and Its Effect on Postprandial Metabolism in Comparison to Subcutaneous Insulin". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00850161. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*